Progentec Diagnostics

Progentec Diagnostics

Progentec Diagnostics is a clinical-stage diagnostics company focused on autoimmune disease detection. Founded by a team including Dr. Alok Tyagi and others, the firm applies proteomics and machine learning to identify biomarkers for conditions that have long lacked objective diagnostic tools. The lead program targets Sjögren's disease, a systemic autoimmune disorder that affects an estimated 4 million people in the U.S. alone, many of whom go undiagnosed for years (per public record). Progentec's platform combines a proprietary diagnostic blood test with a digital patient monitoring app. The test detects autoantibodies and inflammatory protein signatures; the software tracks symptoms and disease activity in real time. The company is pursuing FDA clearance for its Sjögren's test, aiming to become the first regulatory-approved diagnostic for this indication. Early studies published in peer-reviewed journals report sensitivity and specificity metrics comparable to or exceeding existing late-stage research tools (per public record). The firm has raised venture funding from investors including Cortes Capital and others in the Southwest and Gulf regions. Progentec maintains dual headquarters in Oklahoma City and Abu Dhabi, positioning it for clinical trials and commercial access in both the U.S. and Middle East. The company's team includes PhD scientists, clinical rheumatologists, and regulatory specialists; total headcount is not disclosed. Progentec's structural differentiator is its vertical integration of diagnostic development and digital health deployment. By pairing a wet-lab biomarker assay with a patient-facing mobile app, the firm creates a closed-loop data system — collecting real-world symptom data to refine test algorithms. This model is rare among autoimmune diagnostic startups, which typically focus on either lab or software but not both simultaneously.